Trials / Recruiting

RecruitingNCT07491016

Efficacy and Safety of Telitacicept Combined With Baricitinib for Refractory Rheumatoid Arthritis

A Study on the Clinical Efficacy and Safety of Telitacicept Combined With Baricitinib in the Treatment of Difficult-to-Treat Rheumatoid Arthritis (D2T RA)

Status: Recruiting
Phase: —
Study type: Observational
Enrollment: 30 (estimated)

Sponsor: Zhejiang Provincial People's Hospital · Academic / Other
Sex: All
Age: 18 Years – 85 Years
Healthy volunteers: —

Summary

The aim of this study is to observe the clinical efficacy and safety of telitacicept combined with baricitinib in the treatment of D2TRA patients

Conditions

Telitacicept
Treatment Compliance
Rheumatoid Arthritis

Timeline

Start date: 2026-03-01
Primary completion: 2027-03-30
Completion: 2028-03-30
First posted: 2026-03-24
Last updated: 2026-03-30

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT07491016. Inclusion in this directory is not an endorsement.